RT is a triple hormone agonist that activates the receptors for glucagon(GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon.
Significant weight loss: It can lead to substantial weight loss, with an average reduction of 15-24% body weight over 48 weeks.
Improved glycemic control: It may help regulate blood sugar levels by stimulating insulin secretion and reducing glucagon production.
Reduced cardiovascular risk factors: Studies have indicated that retatrutide may improve blood pressure, cholesterol, and other cardiovascular risk factors.
Improved metabolic health: Retatrutide can improve liver function, reduce inflammation, and enhance overall metabolic health.
Lowered blood pressure: Clinical trial participants experienced reductions in both systolic and diastolic blood pressure.
Improved cholesterol: The drug significantly lowered total and LDL (“bad”) cholesterol, as well as triglycerides, which are fats in the blood.
Reduced fat particles: RT notably reduced the number of atherogenic (plaque-forming) small LDL particles, which are a major risk factor for heart disease.
Reviews
There are no reviews yet.